期刊文献+

肥厚型心肌病患者血浆基质金属蛋白酶-1水平与左心室流出道梗阻关系的研究 被引量:2

Relationship between level of plasma MMP-1 and left ventricular outflow tract obstruction in patientswith hypertrophic cardiomyopathy
下载PDF
导出
摘要 目的探讨肥厚型心肌病(HCM)患者血浆基质金属蛋白酶-1(MMP-1)水平与左心室流出道梗阻的关系。方法纳入肥厚型心肌病患者72例,以基质金属蛋白酶-1(MMP-1)平均水平5.13 ng/ml为界将患者分为高MMP-1组(n=34)和低MMP-1组(n=38),分析两组患者性别、年龄、超声影像学等相关指标差异及与MMP-1相关的指标,同时比较梗阻性HCM与非梗阻性HCM患者的MMP-1水平差异。结果与低MMP-1组比较,高MMP-1组患者在年龄、氨基末端脑钠肽前体(NT-proBNP)、左心室流出道最大压差(LVOTPG)、左心室射血分数(LVEF)、左室后壁宽度(LVPWD)五项指标上存在统计学差异(P<0.05)。NT-proBNP与MMP-1呈正相关(r=0.521,P=0.025),LVOTPG与MMP-1呈正相关(r=0.596,P=0.018),LVEF与MMP-1呈负相关(r=-0.471,P=0.031),LVPWD与MMP-1无显著相关性。梗阻性HCM患者较非梗阻性HCM患者的MMP-1水平显著升高,差异有统计学意义(P<0.05)。结论 MMP-1与NT-proBNP、LVOTPG、LVEF有相关性,在肥厚型心肌病患者左心室流出道梗阻的判断中有一定的价值。 Objective To discuss the relationship between level of plasma matrix metalloproteinase-1 (MMP-1) and left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy (HCM). Methods HCM patients (n=72) were divided into high MMP-1 group (n=34) and low MMP-1 group (n=38) taken average level of MMP-1 (5.13 ng/mL) as a bound. The difference in indexes of sex, age and ultrasound image, and correlation between these indexes and MMP-1 were analyzed. The level of MMP-1 was compared between the patients with obstructive HCM and those with non-obstructive HCM. Results The comparison between low MMP-1 group and high MMP-1 group showed that there were statistical differences in age, NT-proBNP, LVOTPG, LVEF and LVPWD (P〈0.05). NT-proBNP was positively correlated to MMP-1 (r=0.521, P=0.025), LVOTPG was positively correlated to MMP-1 (r=0.596, P=0.018), LVEF was negatively correlated to MMP-1 (r=-0.471, P=0.031), and LVPWD was not correlated to MMP-1. The relation between age and MMP-1 showed a nonlinear correlation. The level of MMP-1 increased significantly in the patients with obstructive HCM compared with those with non-obstructive HCM (P〈0.05). Conclusion MMP-1 is correlated to NT-proBNP, LVOTPG and LVEF, which is valued to the diagnosis of left ventricular outflow tract obstruction in HCM patients.
作者 湛疆 张淳
出处 《中国循证心血管医学杂志》 2014年第1期68-70,共3页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 基质金属蛋白酶-1 肥厚型心肌病 流出道梗阻 Matrix metalloproteinase-1 Hypertrophic cardiomyopathy Outflow tract obstruction
  • 相关文献

参考文献13

  • 1Maron BJ. Hypertrophic cardiomyopathy: a systematic review[J]. JAMA,2002,16(287):1308-20.
  • 2Riekem C,Wilke NM,Jerosch-Herold M,et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy[J]. Cimulation,2005,9( 112):855-61.
  • 3Mann DL,Sponale FG. Activation of matrix metalloproteinase in the failing human heart: breaking the tie that binds[J]. Circulation,1998,98 (17): 1699-702.
  • 4Millat G,Bouvagnet P,Chevalier P,et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy[J]. Eur J Med Genet,2010,53(5):261.
  • 5Richard P,Charron P,Carrier L,et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy[J]. Circulation,2003,107(17):2227-32.
  • 6Yamazaki T,Lee JD,Shimizu H,et al. circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure [J]. Eur J Heart Fail,2004,6(1):41-5.
  • 7Report of the 1995 World Health 0rganization/International society and federation of cardiology task force3 on the definition and classification of cardiomyopathy[J]. Circulation, 1996,9(93):841-2.
  • 8房芳,李治安,赵映,杨娅,栾姝蓉,裴金凤,孙琳,刘文旭.肥厚性心肌病心肌功能及收缩同步性斑点追踪显像评价[J].中国医学影像技术,2008,24(6):877-880. 被引量:23
  • 9于心亚,乔树宾.对肥厚型心肌病认知与治疗手段的变革-2011年ACCF,AHA肥厚型心肌病诊治指南解读[J].中国循环杂志.2012,27(z1):55-9.
  • 10Fassbach M,Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction[J]. Z kardiol,2005,94(5):328-35.

二级参考文献12

  • 1Spirito P,Rapezzi C,Bllone P,et al.Infective endocarditis in hypertrophic cardiomyopathy.Circulation,1999,99:2 132-2 137
  • 2Ninomiya M,Takamoto S,Kotsuka Y,et al.Hypertrophic obstructive cardiomyopathy associated with mitral regurgitation due to infective endocarditis.Jpn Thorac Cardiovasc Surg,2000,48(12):820-823
  • 3Iung B,Rousseau Paziaud J,Cormier B,et al.Contemporary results of mitral valve repair for infective endocarditis.JACC,2004,43:386-392
  • 4Araujo AQ, Arteaga E, Ianni BM, et al. Usefulness of a new pro posed tissue Doppler imaging global function index in hypertrophic cardiomyopathy. Echocardiography, 2006,23(3) : 197- 201.
  • 5Pavlopoulos H. Nihoyannopoulos P. Strain and strain rate deform ation parameters : from tissue Doppler to 2D speckle tracking. Int J Cardiovasc Imaging. 2007,12 [Epub ahead of print].
  • 6Gorcsan J 3rd, Tanabe M, Bleeker GB, et ah Combined longitudi nal and radial dyssynchrony predicts ventricular response after re synchronization therapy. J Am Coil Cardiol, 2007,50 ( 15 ) : 1476- 1483.
  • 7Marian AJ. Pathogenesis of diverse clinical and pathological pheno types in hypertrophic cardiomyopathy. Lancet, 2000,355(9197): 58-60.
  • 8Ennis DB, Epstein FH. Kellman P, et aI. Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging. Magn Reson Med, 2003, 50 (3) : 638- 642.
  • 9Kato TS, Noda A, Izawa H, et al. Discrimination of nonobstruclive hypertrophic eardiomyopathy from hypertensive left ventricu lar hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation, 2004,110(25) : 3808-3814.
  • 10Nagakura T, Takeuchi M, Yoshitani H, et al. Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy. Echocar diography, 2007,24(7):677-684.

共引文献23

同被引文献47

  • 1赵航,舒先红.肥厚型心肌病预后评估的研究进展[J].心血管病学进展,2007,28(1):33-36. 被引量:6
  • 2王俊宏,张寄南.肌钙蛋白Ⅰ突变致肥厚型心肌病的发病机制[J].国际心血管病杂志,2007,34(4):274-276. 被引量:1
  • 3OMAHONY C ,ELLIOTY P M. Prevention of sudden cardiac death in hypertrophic cardiomyopathy [ J ]. Heart ,2014,100 (3) :254-260.
  • 4GERSH B J,MARON B J,BONOW R O,et al. 2011 ACCF/AHA guideline for the diagnosis and~treatment of hypertrophic cardiomyop- athy : a report of the American College of Cardiology Foundation/A- merican Heart Association Task Force on Practice Guidelines [ J ]. Circulation ,2011,124 (24) : e783-e831.
  • 5ELLIOTE P, MCKENNA W J. Hypertrophic cardiomyopathy [ J ]. Lancet ,2004,363 (9424) : 1881-1891.
  • 6PAOLO S, AUTORE C, CLAUDIO R, et al. Scope and risk of sudden death in hypertrophic cardiomyopathy [ J ]. Circulation, 2009, 119 (13) :1703-1710.
  • 7MUNCH J, AYDIN A, SULING A, et al. Orthostatic blood pressure test for risk stratification in patients with hypertrophic cardiomyopathy [J]. PLoS One,2015,10(6) :e0131044.
  • 8KATRITSIS D G, ZAREBA W, CAMM A J, et al. Non-sustained ven- tricular tachycardia [ J ]. J Am Coil Cardiol, 2012,60 ( 20 ) : 1993- 2004.
  • 9ARIS A, ARIEMISIA T, ANGELOS R, et al. Risk factors in hyper- trophic cardiomyopathy [ J ]. Hellenic J of Cardio1,2013,54 (4) :281 - 288.
  • 10BOSTAN C, SINAN U Y, CANBOLAT P, et al. Factors predicting long-term mortality in patients with hypertrophic cardiomyopathy [ J~. Echocardiography ,2014,31 ( 9 ) : 1056-1061.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部